ADIM
ADMA icon

Alpha DNA Investment Management’s ADMA Biologics ADMA Stock Holding History

Alpha DNA Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-40,277
Closed -$450K – 194
2024
Q2 		$450K Sell
40,277
-51,347
-56% -$431K 0.17% 133
2024
Q1 		$605K Buy
+91,624
New +$501K 0.22% 102

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Alpha DNA Investment Management's ADMA Position: Q3 2024 in Review

Alpha DNA Investment Management sold out of ADMA Biologics (ADMA) in Q3 2024, closing a stake of 40,277 shares — an estimated $450K sold.

Alpha DNA Investment Management first reported a position in ADMA in Q1 2024 and held it in 2 quarters. The position peaked at $605K in Q1 2024. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • Alpha DNA Investment Management reported no remaining ADMA Biologics position as of Q3 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 40,277 ADMA Biologics shares in Q3 2024, an estimated $450K.
  • Alpha DNA Investment Management first reported a position in ADMA Biologics in Q1 2024 and held it in 2 quarters.
  • Alpha DNA Investment Management's ADMA Biologics position peaked at $605K in Q1 2024.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Alpha DNA Investment Management's 13F filing for Q3 2024, filed 12 Nov 2024.